CG
AXDX

Cutler Group’s Accelerate Diagnostics AXDX Stock Holding History

Cutler Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-560
Closed -$2K – 3909
2018
Q3 		$2K Sell
560
-1,310
-70% -$290K ﹤0.01% 3445
2018
Q2 		$24K Sell
1,870
-4,560
-71% -$1.02M ﹤0.01% 2061
2018
Q1 		$119K Buy
6,430
+3,250
+102% +$854K 0.01% 1074
2017
Q4 		$79K Buy
3,180
+140
+5% +$32.8K ﹤0.01% 1528
2017
Q3 		$48K Sell
3,040
-2,790
-48% -$685K ﹤0.01% 2274
2017
Q2 		$35K Buy
5,830
+3,350
+135% +$908K ﹤0.01% 2836
2017
Q1 		$14K Buy
2,480
+1,200
+94% +$274K ﹤0.01% 3691
2016
Q4 		$41K Sell
1,280
-20
-2% -$4.75K ﹤0.01% 2740
2016
Q3 		$3K Sell
1,300
-60
-4% -$13.3K ﹤0.01% 5309
2016
Q2 		$36K Buy
1,360
+1,070
+369% +$143K ﹤0.01% 2696
2016
Q1 		$26K Buy
+290
New +$40.9K ﹤0.01% 2991

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Cutler Group's AXDX Position: Q3 2021 in Review

Cutler Group sold out of Accelerate Diagnostics (AXDX) in Q3 2021, closing a stake of 240 shares — an estimated $19K sold.

Cutler Group first reported a position in AXDX in Q4 2015 and held it in 16 quarters. The position peaked at $835K in Q2 2017. 105 funds tracked by Wall St. Rank hold AXDX as of Q3 2021.

  • Cutler Group reported no remaining Accelerate Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 240 Accelerate Diagnostics shares in Q3 2021, an estimated $19K.
  • Cutler Group first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 16 quarters.
  • Cutler Group's Accelerate Diagnostics position peaked at $835K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.